Heart valve disease is third cardiac condition in the U.S.affecting 2.5% of adult population. There are multiple questions with regard to heart valve engineering from basic science to translation. Many unknowns exist related to calcification and its potential mechanisms in transcatheter heart valve (THV), for example, due to stent crimping that can critically affect the valve durability. This is particularly important as the THV technologies are getting more popular and their indication for use is expanding for younger patients. The other compelling area in heart valve engineering is development of self-regenerating or growth-enabled tissue engineered valves. These technologies can revolutionize the future of heart valve related therapies.